.Pharmacolibrary.Drugs.ATC.A.A10AE05 .Pharmacolibrary.Drugs.ATC.A.A10AE05| name: | InsulinDetemir |
| ATC code: | A10AE05 | route: | subcutaneous |
| n-compartments | 1 |
Insulin detemir is a long-acting human insulin analogue used for the treatment of diabetes mellitus in adults, adolescents, and children aged 1 year and above. It provides basal insulin coverage to help control blood glucose levels and is approved for use in most countries worldwide.
Pharmacokinetic parameters reported for healthy subjects and patients with type 1 diabetes; parameters predominantly from subcutaneous administration in adult males and females.
Jhee, SS, et al., & Jacobsen, LV (2004). Similarity of insulin detemir pharmacokinetics, safety, and tolerability profiles in healthy caucasian and Japanese american subjects. Journal of clinical pharmacology 44(3) 258–264. DOI:10.1177/0091270003262949 PUBMED:https://pubmed.ncbi.nlm.nih.gov/14973299
Rendell, M (2013). Insulin degludec: a long-acting modern insulin analogue with a predictable pharmacokinetic/pharmacodynamic profile. Drugs of today (Barcelona, Spain : 1998) 49(6) 387–397. DOI:10.1358/dot.2013.49.6.1976051 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23807942
Danne, T, et al., & Kordonouri, O (2008). Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Pediatric diabetes 9(6) 554–560. DOI:10.1111/j.1399-5448.2008.00443.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/18761644